Detalhe da pesquisa
1.
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.
Nature
; 603(7903): 934-941, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35130560
2.
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.
Leukemia
; 38(5): 963-968, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38491306
3.
HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL.
Blood Adv
; 7(12): 2758-2771, 2023 06 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36857419
4.
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia.
J Clin Oncol
; 41(2): 354-363, 2023 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36108252
5.
Ligand-switchable substrates for a ubiquitin-proteasome system.
J Biol Chem
; 286(36): 31328-36, 2011 Sep 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-21768107
6.
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy.
Blood Adv
; 6(7): 1961-1968, 2022 04 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34788386
7.
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report.
Blood Adv
; 6(2): 600-610, 2022 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34794180
8.
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.
J Clin Oncol
; 40(9): 945-955, 2022 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34882493
9.
Intracellular context affects levels of a chemically dependent destabilizing domain.
PLoS One
; 7(9): e43297, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22984418